Business Context and Reporting Period
This Form 8-K is a current report filed by Cerecor Inc. (noting a discrepancy in the request metadata which listed "Avalo Therapeutics, Inc.") on June 9, 2020. The filing details the entry into a material definitive agreement regarding an underwritten public offering of common stock.
Key Financial Metrics and Transaction Details
- Offering Size: 13,200,000 shares of Common Stock.
- Public Offering Price: $2.50 per share.
- Underwriter Purchase Price: $2.3651 per share (reflecting a $0.1349 per-share discount).
- Over-Allotment Option: The underwriter (Oppenheimer & Co. Inc.) has a 30-day option to purchase up to an additional 1,980,000 shares at $2.35 per share.
- Expected Net Proceeds: Approximately $30.8 million (excluding the over-allotment option), after deducting underwriting discounts, commissions, and estimated offering expenses.
- Closing Date: Expected on or about June 11, 2020.
Material Changes and Agreements
The primary material change is the execution of an Underwriting Agreement with Oppenheimer & Co. Inc. Key terms include:
- Insider Participation: Certain officers and insiders may purchase shares, though no binding commitments were received at the time of filing. A reduced 2% underwriting discount applies to shares purchased by existing stockholders and third parties.
- Lock-Up Agreements: Directors and executive officers have entered into lock-up agreements prohibiting the sale or transfer of securities for 90 days from the date of the Underwriting Agreement.
- Registration: The offering is made pursuant to a previously effective Form S-3 registration statement (File No. 333-233978).
Outlook, Risks, and Management Commentary
The filing includes standard forward-looking statements regarding the Company's plans and expectations, noting that actual results may differ materially. The Company has filed supplemental risk factors (Exhibit 99.3) related to this offering, which should be read in conjunction with the risk factors in its 2019 Form 10-K and Q1 2020 Form 10-Q. The Company assumes no obligation to update forward-looking statements.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received, as the $30.8 million figure is an estimate excluding the over-allotment option.
- Confirm whether the underwriter exercises the option to purchase the additional 1,980,000 shares within the 30-day window.
- Review the supplemental risk factors in Exhibit 99.3 for specific risks associated with the capital raise.
- Check subsequent filings to determine the extent of insider participation in the offering.